Chitooligosaccharides induce apoptosis in human myeloid leukemia HL-60 cells

被引:38
|
作者
Kim, Eun-Kyung [2 ,4 ]
Je, Jae-Young [3 ]
Lee, Seung-Jae [1 ]
Kim, Yon-Suk [1 ]
Hwang, Jin-Woo [1 ]
Sung, Si-Heung [2 ]
Moon, Sang-Ho [4 ]
Jeon, Byong-Tae [4 ]
Kim, Se-Kwon [5 ]
Jeon, You-Jin [6 ]
Park, Pyo-Jam [1 ,4 ]
机构
[1] Konkuk Univ, Dept Biotechnol, Chungju 380701, South Korea
[2] Konkuk Univ, Dept Food Life Sci, Chungju 380701, South Korea
[3] Chonnam Natl Univ, Dept Food Technol & Nutr, Yeosu 350749, South Korea
[4] Konkuk Univ, Korean Nokyong Res Ctr, Chungju 380701, South Korea
[5] Pukyong Natl Univ, Dept Chem, Pusan 608737, South Korea
[6] Jeju Natl Univ, Fac Appl Marine Sci, Cheju 690756, South Korea
关键词
Hetero-chitooligosaccharide; Deacetylation; Molecular weight; Anticancer; HETERO-CHITOOLIGOSACCHARIDES; ANTIMICROBIAL ACTIVITY; CHITOSAN; CANCER; PREVENTION; WEIGHT;
D O I
10.1016/j.bmcl.2012.08.030
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In this study we propose a novel anticancer agent using hetero-chitooligosaccharide (hetero-COS). To examine the possibility of the hetero-COS as a anticancer agent, we prepared nine kinds of hetero-COS with relatively higher molecular weights (90, 75 and 50-COS I, 5 similar to 10 kDa), medium molecular weights (90, 75 and 50-COS II, 1 similar to 5 kDa), and lower molecular weights (90, 75 and 50-III, below 1 kDa), and their anticancer properties were investigated on HL-60 cells using flow cytometry and morphological analysis. The results obtained indicate that 90-COS III, which is relatively higher degree of deacetylation and lower molecular weights, showed the highest anticancer activity, and the data showed the anticancer property of the hetero-COSs depended on their degree of deacetylation values and molecular weight. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6136 / 6138
页数:3
相关论文
共 50 条
  • [1] Endomorphins, endogenous opioid peptides, induce apoptosis in human leukemia HL-60 cells
    Lin, X
    Chen, Q
    Xue, LY
    Ma, XJ
    Wang, R
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2004, 82 (11) : 1018 - 1025
  • [2] Sasa quelpaviensis leaf extracts induce apoptosis in human leukemia HL-60 cells
    Jang, Mi-Gyeong
    Park, Soo-Young
    Lee, Sun-Ryung
    Choi, Soo-Youn
    Hwang, Joon-Ho
    Ko, Hee-Chul
    Park, Ji-Gweon
    Chung, Wan-Seok
    Kim, Se-Jae
    FOOD SCIENCE AND BIOTECHNOLOGY, 2008, 17 (01) : 188 - 190
  • [3] Effects of paclitaxel on proliferation and apoptosis in human acute myeloid leukemia HL-60 cells
    Yun-feng WAN
    1United Gene Scientific Technology Company
    Acta Pharmacologica Sinica, 2004, (03) : 124 - 130
  • [4] α-tomatine inhibits growth and induces apoptosis in HL-60 human myeloid leukemia cells
    Huang, Huarong
    Chen, Shaohua
    Van Doren, Jeremiah
    Li, Dongli
    Farichon, Chelsea
    He, Yan
    Zhang, Qiuyan
    Zhang, Kun
    Conney, Allan H.
    Goodin, Susan
    Du, Zhiyun
    Zheng, Xi
    MOLECULAR MEDICINE REPORTS, 2015, 11 (06) : 4573 - 4578
  • [5] Effects of paclitaxel on proliferation and apoptosis in human acute myeloid leukemia HL-60 cells
    Wan, YF
    Guo, XQ
    Wang, ZH
    Ying, K
    Yao, MH
    ACTA PHARMACOLOGICA SINICA, 2004, 25 (03) : 378 - 384
  • [6] Quercetin induced apoptosis in human leukemia HL-60 cells
    Xiao, D
    Zhu, SP
    Gu, ZL
    ACTA PHARMACOLOGICA SINICA, 1997, 18 (03): : 280 - 283
  • [7] Securinine induced apoptosis in human leukemia HL-60 cells
    Dong, NZ
    Gu, ZL
    Chou, WH
    Kwok, CY
    ACTA PHARMACOLOGICA SINICA, 1999, 20 (03): : 267 - 270
  • [8] APOPTOSIS INDUCED BY ADENOSINE IN HUMAN LEUKEMIA HL-60 CELLS
    TANAKA, Y
    YOSHIHARA, K
    TSUYUKI, M
    KAMIYA, T
    EXPERIMENTAL CELL RESEARCH, 1994, 213 (01) : 242 - 252
  • [9] Erianin induces apoptosis in human leukemia HL-60 cells
    Li, YM
    Wang, HY
    Liu, GQ
    ACTA PHARMACOLOGICA SINICA, 2001, 22 (11): : 1018 - 1022
  • [10] Notopterol-induced apoptosis and differentiation in human acute myeloid leukemia HL-60 cells
    Huang, Qinwan
    Wang, Lin
    Ran, Qian
    Wang, Jin
    Wang, Chengqiang
    He, Hui
    Li, Li
    Qi, Hongyi
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 1927 - 1940